Stock Analysis
Valbiotis (EPA:ALVAL) Full Year 2022 Results
Key Financial Results
- Revenue: €2.81m (up by €2.52m from FY 2021).
- Net loss: €12.3m (loss widened by 42% from FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Valbiotis Earnings Insights
Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in France.
Performance of the French Biotechs industry.
The company's shares are up 11% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for Valbiotis that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether Valbiotis is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALVAL
Valbiotis
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases.
Exceptional growth potential with adequate balance sheet.
